CCM
ADMA icon

Consonance Capital Management’s ADMA Biologics ADMA Stock Holding History

Consonance Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,558,290
Closed -$3.04M – 36
2020
Q4 		$3.04M Hold
1,558,290
– – 0.28% 32
2020
Q3 		$3.72M Sell
1,558,290
-1,100,000
-41% -$3.02M 0.45% 24
2020
Q2 		$7.79M Sell
2,658,290
-725,000
-21% -$2.08M 0.47% 28
2020
Q1 		$9.74M Sell
3,383,290
-1,783,671
-35% -$6.17M 0.73% 27
2019
Q4 		$20.7M Buy
5,166,961
+51,975
+1% +$227K 1.26% 27
2019
Q3 		$22.8M Sell
5,114,986
-590,366
-10% -$2.47M 2.25% 19
2019
Q2 		$22.1M Buy
5,705,352
+1,117,000
+24% +$4.93M 1.56% 21
2019
Q1 		$17.4M Hold
4,588,352
– – 1.1% 21
2018
Q4 		$11M Buy
4,588,352
+49,057
+1% +$243K 0.81% 20
2018
Q3 		$28.2M Buy
4,539,295
+290,061
+7% +$1.67M 1.52% 23
2018
Q2 		$19.2M Buy
4,249,234
+920,000
+28% +$4.59M 1.24% 22
2018
Q1 		$15.3M Sell
3,329,234
-38,401
-1% -$153K 1.4% 20
2017
Q4 		$10.8M Buy
3,367,635
+2,093,702
+164% +$5.86M 0.98% 19
2017
Q3 		$3.92M Hold
1,273,933
– – 0.43% 17
2017
Q2 		$4.71M Hold
1,273,933
– – 0.56% 17
2017
Q1 		$6.22M Hold
1,273,933
– – 0.65% 21
2016
Q4 		$6.52M Hold
1,273,933
– – 0.72% 20
2016
Q3 		$9.22M Hold
1,273,933
– – 0.89% 18
2016
Q2 		$7.58M Buy
1,273,933
+213,916
+20% +$1.5M 1.07% 17
2016
Q1 		$8.58M Hold
1,060,017
– – 1.3% 16
2015
Q4 		$8.55M Buy
1,060,017
+7,875
+0.7% +$70.9K 1.15% 13
2015
Q3 		$8.8M Buy
1,052,142
+17,421
+2% +$161K 1.24% 16
2015
Q2 		$9.58M Buy
1,034,721
+48,214
+5% +$417K 0.96% 19
2015
Q1 		$9.67M Buy
986,507
+109,100
+12% +$1.1M 0.88% 22
2014
Q4 		$9.8M Buy
+877,407
New +$10M 1.26% 16

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Consonance Capital Management's ADMA Position: Q1 2021 in Review

Consonance Capital Management sold out of ADMA Biologics (ADMA) in Q1 2021, closing a stake of 1,558,290 shares — an estimated $3.04M sold.

Consonance Capital Management first reported a position in ADMA in Q4 2014 and held it in 25 quarters. The position peaked at $28.2M in Q3 2018. 105 funds tracked by Wall St. Rank hold ADMA as of Q1 2021.

  • Consonance Capital Management reported no remaining ADMA Biologics position as of Q1 2021 after selling out during the quarter.
  • Consonance Capital Management sold 1,558,290 ADMA Biologics shares in Q1 2021, an estimated $3.04M.
  • Consonance Capital Management first reported a position in ADMA Biologics in Q4 2014 and held it in 25 quarters.
  • Consonance Capital Management's ADMA Biologics position peaked at $28.2M in Q3 2018.
  • 105 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2021.

Based on Consonance Capital Management's 13F filing for Q1 2021, filed 17 May 2021.